The Motley Fool
20 Nov 2025, 20:01 UTC · 50w ago
Why Exact Sciences Stock Surged Today
Impact · against what's priced in
Exact Sciences is being acquired by Abbott Laboratories for $105 per share in cash, creating a significant immediate premium for EXAS shareholders. For Abbott, the deal provides strategic entry into the $60 billion cancer screening market, though the transaction will not close until Q2 2026.
- EXAS+0.90
No priced-in read yet
- In context
The agreement to be acquired by Abbott for $105 per share represents a nearly 22% premium over the previous close.
Read from the article alone
Top 1 mover · tap to explore
